Insider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) CFO Sells 7,035 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This represents a 3.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kymera Therapeutics Stock Up 1.1 %

Shares of KYMR traded up $0.35 on Friday, reaching $32.89. The stock had a trading volume of 639,628 shares, compared to its average volume of 584,001. Kymera Therapeutics, Inc. has a twelve month low of $29.07 and a twelve month high of $53.27. The firm has a market capitalization of $2.14 billion, a PE ratio of -14.06 and a beta of 2.22. The firm has a 50-day moving average of $38.23 and a 200 day moving average of $43.40.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The firm had revenue of $7.39 million during the quarter, compared to analyst estimates of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Kymera Therapeutics by 27.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock valued at $114,000 after purchasing an additional 504 shares in the last quarter. Harbor Capital Advisors Inc. lifted its stake in Kymera Therapeutics by 30.0% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 40,303 shares of the company's stock valued at $1,908,000 after buying an additional 9,292 shares in the last quarter. Natixis Advisors LLC acquired a new stake in Kymera Therapeutics during the 3rd quarter valued at $681,000. Thrivent Financial for Lutherans acquired a new stake in Kymera Therapeutics during the 3rd quarter valued at $313,000. Finally, Jennison Associates LLC increased its position in Kymera Therapeutics by 85.8% during the third quarter. Jennison Associates LLC now owns 797,681 shares of the company's stock worth $37,754,000 after buying an additional 368,394 shares in the last quarter.

Analyst Upgrades and Downgrades

KYMR has been the topic of a number of recent research reports. Leerink Partners reissued an "outperform" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. Wells Fargo & Company upgraded shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and upped their price objective for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They issued a "market perform" rating and a $55.00 target price on the stock. BTIG Research assumed coverage on shares of Kymera Therapeutics in a research note on Tuesday, December 10th. They set a "buy" rating and a $60.00 price target on the stock. Finally, Stephens restated an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.